At 4.7% CAGR, Asia Pacific Infectious Disease Therapeutics Market is Projected to be worth US$ 37,415.07 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific infectious disease therapeutics market was valued at US$ 25,904.61 million in 2022 and is projected to reach US$ 37,415.07 million by 2030, registering a CAGR of 4.7% from 2022 to 2030. Rising prevalence of infectious disease and increasing focus on funding and R&D in infectious disease therapeutics are among the critical factors attributed to drive the Asia Pacific infectious disease therapeutics market growth.

Research and development (R&D) is a critical part of the business of biopharmaceuticals and pharmaceutical companies. R&D enables them to launch new products for several therapeutic applications with significant medical and commercial potential. Also, leading market players are investing in R&D to develop enhanced technologies and gain more revenue share.

The Indian government has demonstrated previously unseen determination in combating infectious diseases, particularly tuberculosis, by implementing an ambitious national strategy that aims to eradicate the disease by 2025. One of the biggest recipients of grants from the Global Fund is India. The Global Fund has awarded more than US$ 2.36 billion in grants to India for initiatives aimed at combating the three illnesses since 2003 as of November 2020. India has received US$ 500 million from the Global Fund for the 2020–2022 allocation period. Additionally, the National Healthcare Group (NHG), the Agency for Science, Technology and Research (A*STAR), the Lee Kong Chian School of Medicine (LKCMedicine) at Nanyang Technological University, Singapore (NTU Singapore), and the National Centre for Infectious Diseases (NCID) have launched a tripartite program in infectious diseases for new discoveries and treatments (TRIDENT). The collaborative program, which has allocated US$ ~6.65 million in financing, aims to improve knowledge and capacities to address three priority disease areas while also expediting local research in infectious diseases. The primary infectious diseases burden for mortality and morbidity in Singapore was used to identify these disease areas: emerging infectious diseases, respiratory tract infections, and antimicrobial resistance (AMR). Thus, rising focus on R&D and funding in infectious disease therapeutics drive the infectious disease therapeutics market growth.

On the contrary, emergence of anti-infective drugs resistance and associated side effects hamper the growth of the Asia Pacific infectious disease therapeutics market.

Based on drug class, the Asia Pacific infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held 44.4% market share in 2022, amassing US$ 11,509.82 million. It is projected to garner US$ 16,781.44 million by 2030 to register 4.8% CAGR during 2022–2030.

In terms of indication, the Asia Pacific infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV segment held 35.9% share of Asia Pacific infectious disease therapeutics market in 2022, amassing US$ 9,308.72 million. It is anticipated to garner US$ 13,884.60 million by 2030 to expand at 5.1% CAGR during 2022–2030.

Based on route of administration, the Asia Pacific infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held 55.7% market share in 2022, amassing US$ 14,431.15 million. It is projected to garner US$ 21,172.07 million by 2030 to register 4.9% CAGR during 2022–2030.

In terms of distribution channel, the Asia Pacific infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held 49.1% share of Asia Pacific infectious disease therapeutics market in 2022, amassing US$ 12,717.11 million. It is anticipated to garner US$ 18,751.24 million by 2030 to expand at 5.0% CAGR during 2022–2030.

Based on country, the Asia Pacific infectious disease therapeutics market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 27.4% share of Asia Pacific infectious disease therapeutics market in 2022. It was assessed at US$ 7,092.19 million in 2022 and is likely to hit US$ 10,577.83 million by 2030, registering a CAGR of 5.1% during 2022–2030.

Key players operating in the Asia Pacific infectious disease therapeutics market are AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd, among others.

• In June 2022, GSK plc invested £1bn over ten years to accelerate research and development (R&D) dedicated to infectious diseases that disproportionately impact lower-income countries. This research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR), which continue to have a devastating toll on the most vulnerable, accounting for more than 60% of the disease burden in many lower-income countries.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com